top of page

About Us

History

StemInov is a clinical stage company, spin-off from Nancy’s Teaching Hospital and Lorraine Region’s Uni.

The company develops an off-the-shelf, allogenic stem cell therapy treatment, in the field of inflammatory pathologies, with a focus on critical care.

The company's lead product candidate “WhartSep” is based on Stem cells from Wharton jelly of the umbilical cord (WJ-MSC) and classified by the EMA (European Medicines Agency) as an ATMP (Advanced-Therapy Medicinal Product).

WhartSep is a new concept in immunomodulation and adaptive medicine thanks to its immunomodulation properties.

Our first indication is the patented treatment of severe pneumonia in entry of phase Ib

Technology

Capture d’écran 2022-10-24 à 17.46.23.png

Management Team

Consultants

PARTNERS

R&D

Support

Logo chu.png
Logo UL.png
Logo Grand est region.png
logo IL.png
Logo BPI .png
Logo sayens.png

Labels

i-Lab_600x400_1050515_1050656.jpeg

StemInov SAS
2 avenue de la Forêt de Haye
54520 VANDOEUVRE-LES-NANCY

  • LinkedIn
Logo_FrenchTech_Health20_2023.png

© 2023 by StemInov - All rights reserved

bottom of page